Toleranzia AB Logo

Toleranzia AB

TOL | ST

Overview

Corporate Details

ISIN(s):
SE0007438577 (+1 more)
LEI:
529900ARVN1D3A4CHI81
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Toleranzia AB is a biotechnology company developing therapies that utilize the immune system to treat rare autoimmune (orphan) diseases. The company's approach focuses on targeting the underlying cause of a disease, aiming to create curative or long-acting treatments that go beyond symptom management. Its lead drug candidate, TOL2, is in development for the treatment of the neuromuscular disease myasthenia gravis (MG). Toleranzia's pipeline also includes TOL3, a candidate for the treatment of the autoimmune blood vessel disease ANCA-vasculitis.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Toleranzia AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Toleranzia AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Toleranzia AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-04 Thomas Eldered Other Sell 12,000,000 5,100,000.00 SEK
2025-04-03 Thomas Eldered Other Sell 23,764,705 10,099,999.62 SEK

Peer Companies

Company Country Ticker View
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
Molecure S.A. Logo
Developing first-in-class small molecule drugs for cancer and inflammatory/fibrotic diseases.
Poland MOC
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
Nanobiotix Logo
Developing physics-based nanotherapeutics that amplify radiotherapy to treat solid tumors.
France NANO
NanoGroup S.A. Logo
Develops nanotech medical solutions for oncology, transplantology, diagnostics, and therapy.
Poland NNG
Nattaro Labs AB Logo
Develops research-based, sustainable solutions for bed bug prevention, detection, and control.
Sweden NATTA
Neovacs Logo
Develops therapeutic vaccines for autoimmune diseases & allergies, while investing in BioTech/MedTech.
France ALNEV
Newron Pharmaceuticals S.p.A. Logo
Developing novel therapies for CNS diseases like Parkinson's and schizophrenia.
Italy NWRN